A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Qilu Pharmaceutical Co., Ltd.
Genmab
AstraZeneca
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
Inspirna, Inc.
Sun Yat-sen University
Sanofi